September 4, 2019 | Vensana in the News

Co-founded by Versant, NEA investors, new medtech VC firm kicks off inaugural fund with $225M bounty

20

Novel FDA PMA & de novo 510k approvals

55

U.S. Commercial Product Launches

39

Level I Clinical Trials

29

Strategic Financings

30

Exits by IPO or M&A